New Zealand markets open in 4 hours 43 minutes

BIIB Jun 2023 205.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
83.740.00 (0.00%)
As of 11:43AM EST. Market open.
Full screen
Loading interactive chart…
  • GlobeNewswire

    Lecanemab Receives Priority Review Status in Japan

    TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Minis

  • Zacks

    Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

    Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

  • GlobeNewswire

    Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

    TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of